VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Adjuvant arthritis DNA vaccine pcDNA-CCOL2A1 encoding type II collagen
Vaccine Information
  • Vaccine Name: Adjuvant arthritis DNA vaccine pcDNA-CCOL2A1 encoding type II collagen
  • Target Pathogen: Arthritis
  • Vaccine Ontology ID: VO_0004410
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Rat
  • Collagen type II gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pcDNA3 expressed chicken type II collagen (CCOL2A1) (Song et al., 2009).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pcDNA3.1 DNA vaccine plasmid
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Rat Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: CD4+CD25+Treg cells play a role in restraining auto-aggressive T cells in experimental settings, and 200 μg/kg of pcDNA-CCOL2A1vaccine increased the proportion of CD4+CD25+Treg cells in the blood of arthritic rats compared with those in all other groups (Song et al., 2009).
  • Efficacy: Comparison of all treated and control groups demonstrated clearly that 200 μg/kg of pcDNA-CCOL2A1 vaccine alone in a single intravenous treatment significantly reduced the severity of disease, footpad swelling, arthritic incidence, clinical scores, and deferred the onset of disease (Song et al., 2009).
  • Host IgG (partial) response
    • Description: pcDNA-CCOL2A1 vaccine significantly reduced the levels of serum anti-CII IgG antibodies compared to the negative control group (P < 0.05) (Song et al., 2009).
    • Detailed Gene Information: Click Here.
  • Host Il10 from Rattus norvegicus response
    • Description: Concentrations of the Th2-cytokine IL-10 in 200 μg/kg of pcDNA-CCOL2A1 vaccine group were significantly higher than those in all other groups, including the MTX positive control group (P < 0.05) (Song et al., 2009).
    • Detailed Gene Information: Click Here.
  • Host TGF-B from Rattus norvegicus response
    • Description: Concentrations of the Th3-cytokine TGF-β in 200 μg/kg of pcDNA-CCOL2A1 vaccine group were significantly higher than those in all other groups, including the MTX positive control group (P < 0.05) (Song et al., 2009).
    • Detailed Gene Information: Click Here.
  • Host TNF-alpha from Rattus norvegicus response
    • Description: Concentrations of the Th1-cytokine TNF-α in both 200 μg/kg of pcDNA-CCOL2A1 vaccine and MTX groups were significantly lower than those in the negative control and other treatment groups (P < 0.05). Of note, the level of TNF-α in 200 μg/kg of pcDNA-CCOL2A1 vaccine group recovered to that of the normal group (Song et al., 2009).
    • Detailed Gene Information: Click Here.
References
Song et al., 2009: Song X, Liang F, Liu N, Luo Y, Xue H, Yuan F, Tan L, Sun Y, Xi C, Xi Y. Construction and characterization of a novel DNA vaccine that is potent antigen-specific tolerizing therapy for experimental arthritis by increasing CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Vaccine. 2009; 27(5); 690-700. [PubMed: 19095031].